Posted by Michael Wonder on 27 Dec 2021
Ligand’s Partner CStone Pharmaceuticals receives approval in China for sugemalimab (Cejemly) for the first-line treatment of advanced non-small-cell lung cancer in combination with chemotherapy
22 December 2021 - Sugemalimab was discovered using the OmniAb platform.
Ligand Pharmaceuticals Incorporated today announced that its partner CStone Pharmaceuticals has received approval from China’s National Medical Products Administration for sugemalimab (Cejemly), an OmniAb-derived anti-PD-L1 monoclonal antibody, for the first-line treatment of metastatic non-small cell lung cancer in combination with chemotherapy.
